Nippon Kayaku Co Ltd - Company Profile
Powered by
All the data and insights you need on Nippon Kayaku Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Nippon Kayaku Co Ltd Strategy Report
- Understand Nippon Kayaku Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Nippon Kayaku Co Ltd (Nippon Kayaku) is a chemical company, which undertakes the development, manufacturing and sale of functional chemicals, pharmaceuticals, safety systems and agrochemicals. The company's product portfolio includes epoxy resins, UV-curing type resins, optical functional films, colors for inkjet printers, catalysts, pharmaceuticals, active pharmaceutical ingredients, intermediates, diagnostic drugs, safety systems such as airbag inflators, micro gas generators for seatbelt pretensioners, squibs, agrochemicals, dyes and others. The company also offers real estate leasing and contract manufacturing to pharmaceutical companies. The company has subsidiaries in companies in North America, Europe and Asia. Nippon Kayaku is headquartered in Chiyoda-ku, Tokyo, Japan.
Nippon Kayaku Co Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
UV-curing Type Resins | Bren |
Optical Functional Films | Carboplaten |
Colors for Inkjet Printers | Coforin |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, the company entered into a licensing and commercialization agreement with BioCheetah to expand and market a novel urinary biomarkers-based bladder cancer diagnostic assay kit, VECanDx ELISA in Japan. |
2023 | Contracts/Agreements | In October, the company entered into an exclusive license agreement with AnHeart Therapeutics to market and distribute AnHeart’s lead investigational therapy, taletrectinib, in Japan. |
2023 | New Products/Services | In June, the company announced the launch of Anticancer Agent/Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Erlotinib Tablets of 25mg. |
Competitor Comparison
Key Parameters | Nippon Kayaku Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Eisai Co Ltd |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Bunkyo-Ku |
State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
No. of Employees | 5,782 | 49,095 | 14,484 | 17,435 | 11,076 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Atsuhiro Wakumoto | Director; President | Executive Board | - | - |
Tomoo Shibuya | Executive Vice President - Legal Affairs Division; Executive Vice President - Secretarial Division; Executive Vice President - Purchasing Division; Director; Executive Vice President - General Affairs Division; Executive Vice President - Human Resources Division | Executive Board | - | 66 |
Yoshimi Inoue | Director; Senior Managing Director, Head-Research & Development Group | Executive Board | 2023 | 65 |
Shigeyuki Kawamura | Director; Head-Safety Systems Group; Managing Director - Mobility & Imaging Business Unit | Executive Board | - | - |
Yoshitsugu Ishida | Senior Managing Director- Corporate Planning Division; Senior Managing Director- Information Systems Division; Senior Managing Director- Corporate Communications Division; Director; Senior Managing Director- Finance & Accounting Division | Executive Board | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward